In breast cancer, deregulation of MYC is most frequent in basal‐like tumors and is associated with resistance to adjuvant chemotherapy (Xu et al, 2010); hence, targeting its dependent pathways could be a good therapeutic strategy. The gene discussed is MYC; the disease is breast cancer.